Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
Stopped The incidence of COVID-19 hospitalization cases decreased to a level that continued enrollment was no longer feasible
Conditions
Interventions
- DRUG: BGE-175
- OTHER: Placebo
Sponsor
BioAge Labs, Inc.